Key Points
- Gregory Friberg sold 6,326 shares of BioMarin at an average price of $60.38 for a total of $381,963.88, leaving him with 37,578 shares (a 14.41% reduction in his holdings); the transaction was disclosed in an SEC filing.
- BioMarin shares trade around $61 (one‑year range $50.76–$73.51) with a market cap of $11.74B and a consensus analyst rating of “Moderate Buy” (average target $87.71); several analysts recently adjusted targets, including Piper Sandler cutting to $84 and Guggenheim to $86 while Wells Fargo raised its target to $75.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) EVP Gregory Friberg sold 6,326 shares of the firm's stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the sale, the executive vice president directly owned 37,578 shares of the company's stock, valued at $2,268,959.64. This represents a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
BioMarin Pharmaceutical Stock Down 0.5%
Shares of NASDAQ BMRN opened at $61.11 on Friday. BioMarin Pharmaceutical Inc. has a one year low of $50.76 and a one year high of $73.51. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.21 and a quick ratio of 3.10. The business's fifty day moving average price is $58.90 and its 200-day moving average price is $56.15. The stock has a market capitalization of $11.74 billion, a PE ratio of 34.33, a P/E/G ratio of 0.52 and a beta of 0.26.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. CIBC Private Wealth Group LLC raised its position in shares of BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock worth $39,000 after buying an additional 179 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its stake in BioMarin Pharmaceutical by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company's stock worth $2,554,000 after acquiring an additional 183 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 7.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company's stock valued at $163,000 after acquiring an additional 195 shares in the last quarter. Sittner & Nelson LLC boosted its position in shares of BioMarin Pharmaceutical by 6.9% during the 2nd quarter. Sittner & Nelson LLC now owns 3,100 shares of the biotechnology company's stock valued at $170,000 after acquiring an additional 200 shares during the last quarter. Finally, Grandfield & Dodd LLC boosted its position in shares of BioMarin Pharmaceutical by 1.2% during the 3rd quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company's stock valued at $1,027,000 after acquiring an additional 217 shares during the last quarter. Institutional investors own 98.71% of the company's stock.
Analyst Ratings Changes
BMRN has been the subject of several recent research reports. Piper Sandler reduced their target price on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an "overweight" rating for the company in a research note on Friday, February 6th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of BioMarin Pharmaceutical in a report on Monday, December 29th. Guggenheim reduced their price objective on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a "buy" rating for the company in a research note on Wednesday. Wells Fargo & Company increased their target price on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Finally, Barclays assumed coverage on BioMarin Pharmaceutical in a research report on Wednesday, January 28th. They issued an "overweight" rating and a $80.00 price target for the company. Fifteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $87.71.
Get Our Latest Stock Analysis on BMRN
BioMarin Pharmaceutical Company Profile
(
Get Free Report)
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company's commercial portfolio includes several approved therapies targeting inherited disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
